Acute myocardial infarction (AMI) is a serious threat to human health. Long non-coding RNAs (lncRNAs) are known to be involved in the progression of AMI. The objective of this paper was to explore the functional effect of lncRNA testis-specific transcript Y-linked 15 (TTTY15) on hypoxia-induced cardiomyocyte injury. Human cardiomyocytes AC16 were cultured under hypoxic conditions to induce cardiomyocyte injury. Quantitative real-time polymerase chain reaction (qRT-PCR) was employed to check the expression of TTTY15, microRNA let-7b, and Mitogen-activated protein kinase 6 (MAPK6). Western blot was implemented for protein detection. Cell viability and apoptosis were examined by Cell counting kit-8 (CCK-8) assay and flow cytometry, respectively. The target association among TTTY15, let-7b, and MAPK6 was validated by dual-luciferase reporter assay, pull-down assay and RNA immunoprecipitation (RIP) assay. We found that the abundances of TTTY15 and MAPK6 were elevated, while let-7b level declined in hypoxia-induced AC16 cells. Knockdown of TTTY15 increased cell viability, and inhibited apoptosis of hypoxia-induced AC16 cells. TTTY15 bound to and inversely regulated let-7b. Likewise, MAPK6 was a target of let-7b and was negatively regulated by let-7b. Silencing of TTTY15 ameliorated the impact of let-7b downregulation or MAPK6 upregulation on hypoxia-induced cardiomyocyte injury. TTTY15 modulated MAPK6 enrichment by sponging let-7b. In conclusion, knockdown of TTTY15 suppressed hypoxia-induced cardiomyocyte injury through the let-7b/MAPK6 axis.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7476952PMC

Publication Analysis

Top Keywords

cardiomyocyte injury
16
hypoxia-induced cardiomyocyte
12
ttty15
10
long non-coding
8
let-7b/mapk6 axis
8
let-7b
8
cell viability
8
hypoxia-induced ac16
8
ac16 cells
8
knockdown ttty15
8

Similar Publications

Background: Vascular endothelial growth factor (VEGF) and VEGF receptor (VEGFR) inhibitors play a pivotal role in treating various tumors; however, the clinical characteristics and molecular mechanisms of their associated heart failure (HF) remain incompletely understood.

Methods: We investigated the epidemiological characteristics of VEGF or VEGFR inhibitors [VEGF(R)i]-related heart failure (VirHF) using the global pharmacovigilance database Vigibase. The phenotypic features and molecular mechanisms of VirHF were characterized using VEGF(R)i-treated mouse models through a combination of echocardiography, histopathological analysis, and transcriptome sequencing.

View Article and Find Full Text PDF

Mitochondrial dysfunction and ferroptosis play crucial roles in myocardial ischemia/reperfusion (I/R) following heart transplantation. Microsomal glutathione s transferase 1 (MGST1) is widely distributed in mitochondria and has a protective effect against ferroptosis, and its involvement in myocardial I/R injury has not yet been elucidated. In this study, donor hearts from C57BL/6 male mice were subjected to 12 h of ex-vivo cold ischemia treatment and transplanted into the abdomen of recipient mice for 24 h of reperfusion.

View Article and Find Full Text PDF

SS-31@Fer-1 Alleviates ferroptosis in hypoxia/reoxygenation cardiomyocytes via mitochondrial targeting.

Biomed Pharmacother

January 2025

Department of Cardiology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai 200120, China. Electronic address:

Purpose: Targeting mitochondrial ferroptosis presents a promising strategy for mitigating myocardial ischemia-reperfusion (I/R) injury. This study aims to evaluate the efficacy of the mitochondrial-targeted ferroptosis inhibitor SS-31@Fer-1 (elamipretide@ferrostatin1) in reducing myocardial I/R injury.

Methods: SS-31@Fer-1 was synthesized and applied to H9C2 cells subjected to hypoxia/reoxygenation (H/R) to assess its protective effects.

View Article and Find Full Text PDF

Unlabelled: Enteroviruses cause nearly 1 billion global infections annually and are associated with a diverse array of human illnesses. Among these, myocarditis and the resulting chronic inflammation have been recognized as major contributing factors to virus-induced heart failure. Despite our growing understanding, very limited therapeutic strategies have been developed to address the pathological consequences of virus-induced chronic innate immune activation.

View Article and Find Full Text PDF

ROS-differentiated release of Apelin-13 from hydrogel comprehensively treats myocardial ischemia-reperfusion injury.

J Control Release

January 2025

Department of Cardiology, Zhongda Hospital, School of Medicine, Southeast University, 87 Dingjiaqiao, Nanjing 210009, China. Electronic address:

Treatment of myocardial ischemia-reperfusion (MI/R) injury still faces the lack of clinically approved drugs. Apelin-13 is a highly promising drug candidate of MI/R injury, but hampered by its extremely short half-life in plasma. This calls for efficient and smart delivering system for Apelin-13 delivery, but has not been reported.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!